Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.

ABSTRACT:

Introduction

Plasma biomarkers of Alzheimer's disease (AD) represent accessible alternatives to positron emission tomography (PET) and cerebrospinal fluid (CSF)-based biomarkers in well-characterized cohorts. It remains to be determined whether performance is maintained in outpatient clinics comprised of patients with multiple causes of cognitive impairment.

Methods

Plasma phosphorylated tau217 (p-tau217) and amyloid beta (Aβ) 42/40 were measured in 509 patients evaluated in a tertiary-care memory clinic. Biomarker performance was compared across diagnoses, referencing established cutpoints for positive and negative biomarkers.

Results

Plasma p-tau217 distinguished patients with diagnoses of symptomatic AD with 95% sensitivity and 82% specificity. Integration of Aβ42

SUBMITTER: Piura YD 

PROVIDER: S-EPMC12142430 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature